{"id":848969,"date":"2025-05-08T07:34:13","date_gmt":"2025-05-08T11:34:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\/"},"modified":"2025-05-08T07:34:13","modified_gmt":"2025-05-08T11:34:13","slug":"relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\/","title":{"rendered":"Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CORAL GABLES, Fla., May  08, 2025  (GLOBE NEWSWIRE) &#8212; Relmada Therapeutics, Inc. (Nasdaq: RLMD, \u201cRelmada\u201d, or \u201cthe Company\u201d), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress.<\/p>\n<p align=\"justify\">Conference Call and Webcast Information:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Date: Monday, May 12, 2025 at 4:30 PM ET<\/li>\n<li style=\"text-align:justify\">Participant Dial-in (US): 1-877-407-0792<\/li>\n<li style=\"text-align:justify\">Participant Dial-in (International): 1-201-689-8263<\/li>\n<li style=\"text-align:justify\">Conference: 13753596<\/li>\n<li style=\"text-align:justify\">Webcast Access: <a href=\"https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1717870&amp;tp_key=a2f4c52c13\" rel=\"nofollow\" target=\"_blank\">Click Here<\/a><\/li>\n<\/ul>\n<p align=\"justify\">A replay of the webcast will be available in the Investors section of the Relmada website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=I41GQ-0IRQVSH-D4WLtOhR6abxMg00V3zHNqcp3O_Ed51Nt973nNQhDmoK1tVogmZ7RpR0lfmom5L165-bIhnkMSzZVj850wBZ3EadjMAG0WJUUPnVsRKGeSemko_veUgfQ-nsxCn4VSrf7FT_3a2gozs4FOz9JGDvGlOhphsRs=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.relmada.com\/investors\/ir-calendar<\/a>.<\/p>\n<p>\n        <strong>About Relmada Therapeutics, Inc. <\/strong><br \/>\n        <br \/>Relmada Therapeutics is a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies that have the potential to bring meaningful clinical benefits to targeted patient populations.<\/p>\n<p>Lead investigational program, NDV-01, for High-Grade Non-Muscle Invasive Bladder Cancer, is being evaluated in a Phase 2 study. In addition, preparations are underway to advance sepranolone, a Phase 2b-ready investigational product for compulsion-related disorders including Tourette\u2019s Syndrome and Prader-Willi Syndrome, into further studies.<\/p>\n<p>For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=62JPRmgCQN96jLPBt4acWYU6eCOPZAnWz5csO6UItiQ7K-Fos7uw6-GZ9CWs8K_GHQODte0UOcHImmfKV77xBw==\" rel=\"nofollow\" target=\"_blank\">www.relmada.com<\/a>. Follow us on LinkedIn.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Brian Ritchie<br \/>LifeSci Advisors<br \/>britchie@lifesciadvisors.com<\/p>\n<p align=\"justify\">\n        <strong>Media Inquiries:<\/strong><br \/>\n        <br \/>Corporate Communications<br \/>media@relmada.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjY4NyM2OTI3OTQ1IzUwMDA5Nzc1Mw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDA1ODY2YTctNjdhOC00NDMzLWIwNTEtYTM5MzYyOWQzZjFmLTUwMDA5Nzc1My0yMDI1LTA1LTA4LWVu\/tiny\/Relmada-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) &#8212; Relmada Therapeutics, Inc. (Nasdaq: RLMD, \u201cRelmada\u201d, or \u201cthe Company\u201d), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress. Conference Call and Webcast Information: Date: Monday, May 12, 2025 at 4:30 PM ET Participant Dial-in (US): 1-877-407-0792 Participant Dial-in (International): 1-201-689-8263 Conference: 13753596 Webcast Access: Click Here A replay of the webcast will be available in the Investors section of the Relmada website at\u00a0https:\/\/www.relmada.com\/investors\/ir-calendar. About Relmada Therapeutics, Inc. Relmada Therapeutics is a clinical-stage biotechnology company committed &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-848969","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) &#8212; Relmada Therapeutics, Inc. (Nasdaq: RLMD, \u201cRelmada\u201d, or \u201cthe Company\u201d), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress. Conference Call and Webcast Information: Date: Monday, May 12, 2025 at 4:30 PM ET Participant Dial-in (US): 1-877-407-0792 Participant Dial-in (International): 1-201-689-8263 Conference: 13753596 Webcast Access: Click Here A replay of the webcast will be available in the Investors section of the Relmada website at\u00a0https:\/\/www.relmada.com\/investors\/ir-calendar. About Relmada Therapeutics, Inc. Relmada Therapeutics is a clinical-stage biotechnology company committed &hellip; Continue reading &quot;Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-08T11:34:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjY4NyM2OTI3OTQ1IzUwMDA5Nzc1Mw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025\",\"datePublished\":\"2025-05-08T11:34:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\\\/\"},\"wordCount\":215,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NjY4NyM2OTI3OTQ1IzUwMDA5Nzc1Mw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\\\/\",\"name\":\"Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NjY4NyM2OTI3OTQ1IzUwMDA5Nzc1Mw==\",\"datePublished\":\"2025-05-08T11:34:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NjY4NyM2OTI3OTQ1IzUwMDA5Nzc1Mw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NjY4NyM2OTI3OTQ1IzUwMDA5Nzc1Mw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\/","og_locale":"en_US","og_type":"article","og_title":"Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - Market Newsdesk","og_description":"CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) &#8212; Relmada Therapeutics, Inc. (Nasdaq: RLMD, \u201cRelmada\u201d, or \u201cthe Company\u201d), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress. Conference Call and Webcast Information: Date: Monday, May 12, 2025 at 4:30 PM ET Participant Dial-in (US): 1-877-407-0792 Participant Dial-in (International): 1-201-689-8263 Conference: 13753596 Webcast Access: Click Here A replay of the webcast will be available in the Investors section of the Relmada website at\u00a0https:\/\/www.relmada.com\/investors\/ir-calendar. About Relmada Therapeutics, Inc. Relmada Therapeutics is a clinical-stage biotechnology company committed &hellip; Continue reading \"Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-08T11:34:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjY4NyM2OTI3OTQ1IzUwMDA5Nzc1Mw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025","datePublished":"2025-05-08T11:34:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\/"},"wordCount":215,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjY4NyM2OTI3OTQ1IzUwMDA5Nzc1Mw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\/","name":"Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjY4NyM2OTI3OTQ1IzUwMDA5Nzc1Mw==","datePublished":"2025-05-08T11:34:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjY4NyM2OTI3OTQ1IzUwMDA5Nzc1Mw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjY4NyM2OTI3OTQ1IzUwMDA5Nzc1Mw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/848969","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=848969"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/848969\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=848969"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=848969"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=848969"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}